The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study

Cost-Effectiveness of Hypertension Therapy According to 2014 Guidelines

(2015) Andrew E. Moran et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prevalence, Awareness, Treatment, and Control of Hypertension in China: Results From a National Survey

(2014) J. Wang et al.   AMERICAN JOURNAL OF HYPERTENSION

ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures

(2014) Jeffrey L. Anderson et al.   CIRCULATION

Cost-Effectiveness of Optimal Use of Acute Myocardial Infarction Treatments and Impact on Coronary Heart Disease Mortality in China

(2014) M. Wang et al.  

Evaluation, in three provinces, of the introduction and impact of China’s National Essential Medicines Scheme

(2013) Yang Li et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

2013 ESH/ESC Guidelines for the management of arterial hypertension

(2013)   EUROPEAN HEART JOURNAL

2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults

(2013) Paul A. James et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Rapid health transition in China, 1990–2010: findings from the Global Burden of Disease Study 2010

(2013) Gonghuan Yang et al.   LANCET

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement

(2013) D. Husereau et al.   BMJ-British Medical Journal

Controlling cost escalation of healthcare: making universal health coverage sustainable in China

(2012) Shenglan Tang et al.   BMC PUBLIC HEALTH

Effects and cost-effectiveness of a guideline-oriented primary healthcare hypertension management program in Beijing, China: results from a 1-year controlled trial

(2012) Xin Wang et al.   HYPERTENSION RESEARCH

Early appraisal of China's huge and complex health-care reforms

(2012) Winnie Chi-Man Yip et al.   LANCET

Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010

(2012) Joshua A Salomon et al.   LANCET

Major inducing factors of hypertensive complications and the interventions required to reduce their prevalence: an epidemiological study of hypertension in a rural population in China

(2011) Min Zhang et al.   BMC PUBLIC HEALTH

Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey

(2011) Salim Yusuf et al.   LANCET

A Cross-Sectional Study of the Microeconomic Impact of Cardiovascular Disease Hospitalization in Four Low- and Middle-Income Countries

(2011) Mark D. Huffman et al.   PLoS One

Future Cardiovascular Disease in China

(2010) Andrew Moran et al.  

The association between socioeconomic status of high-risk patients with coronary heart disease and the treatment rates of evidence-based medicine for coronary heart disease secondary prevention in China: Results from the Bridging the Gap on CHD Secondary Prevention in China (BRIG) Project

(2009) Shaoli Niu et al.   AMERICAN HEART JOURNAL

How willing are the public to pay for anti-hypertensive drugs for primary prevention of cardiovascular disease: a survey in a Chinese city

(2009) J.-L. Tang et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY